According to the clinical practice guidelines for systemic treatment of HER2-positive advanced breast cancer and the principle of treating HER2-positive advanced breast cancer, the selected therapeutic plan recommends targeted therapy combined with chemotherapy and endocrine therapy. The gene discussed is ERBB2; the disease is breast cancer.